ArticleBMC ophthalmology2022
Evaluation of a self-imaging SD-OCT system designed for remote home monitoring.
Article in BMC ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06610747 (Home Care Monitoring of Visual Acuity and OCT Versus Standard Hospital/Clinic Care Monitoring During Diabetic Macular Edema Management), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Home Care Monitoring of Visual Acuity and OCT Versus Standard Hospital/Clinic Care Monitoring During Diabetic Macular Edema Management: A Non-inferiority Randomized Clinical Trial
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Home-monitoring/remote optical coherence tomography in teleophthalmology in patients with eye disorders-a systematic review.Frontiers in medicine · 2024Pooled it
- Home OCT Monitoring as a Safety Net for Early Detection of Recurrent Disease Activity in Neovascular Age-Related Macular Degeneration Under Standard Care.Medicina (Kaunas, Lithuania) · 2026Article
- Longitudinal Validation of the Artificial Intelligence Algorithm in Home OCT for Age-Related Macular Degeneration-Report 3.Ophthalmology science · 2026Article
- Home Monitoring for the Management of Age-Related Macular Degeneration: A Review of the Development and Implementation of Digital Health Solutions over a 25-Year Scientific Journey.Medicina (Kaunas, Lithuania) · 2025Review
- Patients' awareness and presenting symptoms at the onset of neovascular age-related macular degeneration in two distinct European cohorts.International ophthalmology · 2025Article
- Expanding Application of Optical Coherence Tomography Beyond the Clinic: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Article
- [Digital remote monitoring of chronic retinal conditions-A clinical future tool? : Remote monitoring of chronic retinal conditions].Die Ophthalmologie · 2024Review
- Cost-effectiveness of incorporating self-imaging optical coherence tomography into fundus photography-based diabetic retinopathy screening.NPJ digital medicine · 2024Article
- Home Optical Coherence Tomography Monitoring for Neovascular Age-Related Macular Degeneration: Transformative Technology or Cool Toy?Ophthalmology and therapy · 2024Article
- Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study.Ophthalmology. Retina · 2024Observational
- Identification of Genetic Variants for Risk Prediction and Early Diagnosis of Age-Related Macular Degeneration in the Taiwanese Population.International journal of molecular sciences · 2024Article
- Analysis of OCT Scanning Parameters in AMD and RVO.Diagnostics (Basel, Switzerland) · 2024Article
- The impact of COVID-19 on managing ophthalmic diseases: an international, descriptive study.Irish journal of medical science · 2023Article
- Prognostic Optical Coherence Tomography Biomarkers in Neovascular Age-Related Macular Degeneration.Journal of clinical medicine · 2023Review
- Multitask Learning for Activity Detection in Neovascular Age-Related Macular Degeneration.Translational vision science & technology · 2023Article
- Perspectives on the Home Monitoring of Macular Disease.Ophthalmology and therapy · 2023Article
- Asteroid Hyalosis: An Update on Prevalence, Risk Factors, Emerging Clinical Impact and Management Strategies.Clinical ophthalmology (Auckland, N.Z.) · 2023Review
- Polygenic Risk Score Impact on Susceptibility to Age-Related Macular Degeneration in Polish Patients.Journal of clinical medicine · 2022Article
- Advances in Optical Coherence Tomography Imaging Technology and Techniques for Choroidal and Retinal Disorders.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare identification rates of retinal fluid of the Notal Vision Home Optical Coherence Tomography (OCT) device (NVHO) when used by people with age-related macular degeneration (AMD) to those captured by a commercial OCT.
methodsProspective, cross-sectional study where patients underwent commercial OCT imaging followed by self-imaging with either the NVHO 2.5 or the NVHO 3 in clinic setting. Outcomes included patients' ability to acquire analyzable OCT images with the NVHO and to compare those with commercial images.
resultsSuccessful images were acquired with the NVHO 2.5 in 469/531 eyes (88%) in 264/290 subjects (91%) with the mean (SD) age of 78.8 (8.8); 153 (58%) were female with median visual acuity (VA) of 20/40. In the NVHO 3 cohort, 69 eyes of 45 subjects (93%) completed the self-imaging. Higher rates of successful imaging were found in eyes with VA ≥ 20/320. Positive percent agreement/negative percent agreement for detecting the presence of subretinal and/or intraretinal fluid when reviewing for fluid in three repeated volume scans were 97%/95%, respectively for the NVHO v3.
conclusionSelf-testing with the NVHO can produce high quality images suitable for fluid identification by human graders, suggesting the device may be able to complement standard-of-care clinical assessments and treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.